Ikonisys

Founded in 2003 and headquartered in New Haven, USA, Ikonisys has established itself as a premier provider of automated FISH technology for oncology diagnostics. The company's core platform integrates automated microscopy, image analysis, and multiplexed assays to detect genetic alterations and rare circulating tumor cells with high sensitivity and specificity. By automating manual FISH processes, Ikonisys aims to increase lab throughput, reduce human error, and support the growing field of precision medicine. Its solutions target pathology labs seeking to standardize and scale complex genetic testing.

Integrated platform for automated Fluorescence In Situ Hybridization (FISH), combining proprietary automated fluorescence microscopes, image analysis software, and reagent kits to enable operator-free genetic analysis and rare cell detection in cancer diagnostics.

Ikonisys competes in the molecular pathology automation space against large diversified diagnostics companies (e.g., Roche, Abbott, Agilent) that offer FISH reagents and semi-automated systems, as well as smaller specialists in automated imaging and rare cell analysis. Its key differentiator is its focus on full, operator-free FISH automation, but it must contend with the broad market presence and resources of its larger rivals.